<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-04-19T23:43:01Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/2455-8141.000027">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/2455-8141.000027</identifier>
									<datestamp>2024-07-27</datestamp>
									<setSpec>PTZ.Allergy:VOL10</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Stevens-Johnson syndrome due to Lamotrigine
										</dc:title><dc:creator>Silvio Espínola</dc:creator><dc:description>&lt;p&gt;Lamotrigine is an anticonvulsant drug that has been widely used to treat epilepsy, as a mood stabilizer (in cases of bipolar type 1 disorder), and in the management of neuropathic pain; It is used both in monotherapy and in complementary therapy. Considered a relatively new medication, approved by the Food and Drug Administration in 1994, its benefits include a greater margin of safety compared to other anticonvulsants; However, it causes serious adverse skin reactions, such as Stevens-Johnson syndrome. Approximately 8% of patients receiving lamotrigine develop a benign maculopapular rash during the first 4 months of treatment. A case of Stevens-Johnson syndrome caused by the drug is presented and a review of the condition and the probable pathways that trigger this delayed hypersensitivity immune response is carried out.&lt;/p&gt;</dc:description>
										<dc:publisher>Global Journal of Allergy - Peertechz Publications</dc:publisher>
										<dc:date>2024-07-27</dc:date>
										<dc:type>Case Report</dc:type>
										<dc:identifier>https://doi.org/10.17352/2455-8141.000027</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Silvio Espínola et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
